Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer

Abroad (travel likely)Recruiting

Conditions

Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Contact: Study coordinator (Yanqiao Zhang) · yanqiaozhang@ems.hrbmu.edu.cn · 86-138 4512 0210
Contact: Study coordinator (Dan Su)
Baotou Cancer Hospital, Baotou, Inner Mongolia, China
Contact: Study coordinator (Yaqin Tan) · tanyaqin@csco.ac.cn · 86-15848806353
The Second Hospital of Dalian Medical University, Dalian, Liaoning, China
Contact: Study coordinator (Tao Wu) · wiyihong97@163.com · 86-17709872828

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Diffuse Astrocytoma, IDH-Mutant · Glioblastoma, IDH-wildtype · Brain Metastases, Adult

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beverly Hills, United States · Glendale, United States

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Gastric Cancer

Abroad (travel likely)RecruitingPHASE3

Beijing, China

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

Abroad (travel likely)RecruitingPHASE3

Fuzhou, China

Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma

Gastric Cancer

Abroad (travel likely)RecruitingPHASE3

Shanghai, China